Influenza is a highly contagious viral disease, which is primarily spread through water droplets containing strains of the virus. Dr Leong Chee Loon shares his insights into the management of influenza in Malaysia, highlighting the importance of improving vaccination coverage in populations at high-risk of influenza-related complications, such as elderly patients and healthcare practitioners.
At the 13th Asian Congress of Paediatric Nephrology 2017 in conjunction with the 39th Malaysian Paediatric Association Annual Congress, Dr Wanatpreeya Phongsamart spoke on the importance of influenza vaccination in children, highlighting the role of quadrivalent influenza vaccine (QIV) in providing a broader protection against influenza. Meanwhile, Emeritus Professor Somsak Lolekha shared his insights into the effectiveness of a hexavalent vaccine in paediatric immunization, and discussed its role in the Malaysian paediatric immunization schedule.
In this issue of MIMS Anti-Infective Supplement, we bring you clinical updates related to combating infectious diseases, and also a symposium highlight in conjunction with the launch of ceftolozane/tazobactam (Zerbaxa; Merck Sharp & Dohme Sdn Bhd) in Malaysia.
At the recent Asia Pacific Alliance for the Control of Influenza (APACI) workshop in Kuala Lumpur, MIMS Doctor had the privilege of having an exclusive interview with eminent paediatric infectious disease specialist, Associate Professor Tawee Chotpitayasunondh. This article captures the highlights from our conversation with him.
Dengvaxia, a recombinant, live-attenuated dengue vaccine, has the potential to bring down the number of hospitalizations by 13 to 25 percent and be cost-effective in areas of moderate-to-high dengue endemicity, according to a model comparison study.
Intravenous cefiderocol thrice daily is noninferior to imipenem-cilastatin for treating complicated urinary tract infection (UTI) patients with multidrug-resistant, Gram-negative infections, according to a recent study.
In patients with genotype 3 hepatitis C virus (HCV) infection and decompensated cirrhosis, the rate of achieving sustained virologic response 12 weeks after treatment (SVR12) is high with treatment regimens consisting of sofosbuvir and velpatasvir with or without ribavirin, according to the results of a phase II trial. However, the rate appears to be lower in the subgroup of patients with baseline resistance-associated substitutions in nonstructural protein 5A.
In infants with early-life acute respiratory infection (ARI) with respiratory syncytial virus (RSV), elevated nasopharyngeal Lactobacillus levels protect against wheezing illnesses at 2 years of age, a recent study has found.